Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

66
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
66
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

94
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
94
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

572
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
572
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

56
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
56
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

120
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
120

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Creatine Supplementation in Preclinical Models Receiving Immune Checkpoint Inhibitor Therapy: A Systematic Review.

Cureus·2026
Same author

Pulse Wave Velocity in Atrial Fibrillation: A Scoping Review of Clinical Relevance.

Cureus·2026
Same author

Gender-Based Disparities in the Evaluation and Management of Acute Coronary Syndromes.

Cureus·2026
Same author

Janus Kinase and Interleukin-6 Inhibitor-Induced Lipid Modulation and Its Association With Major Adverse Cardiovascular Events in Rheumatoid Arthritis: A Systematic Review of Clinical and Biomarker Evidence.

Cureus·2026
Same author

Biomarkers in the Early Detection of Dementia: A Systematic Review.

Cureus·2026
Same author

Effects of Metformin on Mitochondrial Health and Oxidative Stress in Age-Related Macular Degeneration: A Systematic Review.

Cureus·2026

Related Experiment Video

Updated: Oct 16, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

414

Cardiovascular Risk Associated With TNF Alpha Inhibitor Use in Patients With Rheumatoid Arthritis.

Aaiz Hussain1, Targol Tarahomi2, Lavi Singh3

  • 1Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, USA.

Cureus
|October 18, 2021
PubMed
Summary
This summary is machine-generated.

Tumor necrosis factor (TNF) alpha inhibitors improve rheumatoid arthritis but may increase cardiovascular risks. Our study shows inhibiting the TNFR2 receptor, not TNFR1, likely causes this cardiac morbidity.

Keywords:
congestive heart failureheart failurerheumatoid arthritistnf alphatnf alpha inhibitor

More Related Videos

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.3K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

482

Related Experiment Videos

Last Updated: Oct 16, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

414
Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.3K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

482

Area of Science:

  • Immunology
  • Cardiology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) involves inflammation and joint degradation, often treated with TNF alpha inhibitors.
  • TNF alpha inhibitors effectively manage RA symptoms and immune function.
  • A potential link exists between TNF alpha inhibitors and adverse cardiovascular events, though debated.

Purpose of the Study:

  • Investigate the roles of Tumor Necrosis Factor Receptor 1 (TNFR1) and Tumor Necrosis Factor Receptor 2 (TNFR2) in cardiac tissue.
  • Clarify the mechanisms behind cardiovascular risks associated with TNF alpha inhibitors.

Main Methods:

  • Analysis of TNFR1 and TNFR2 expression and function in cardiac tissue.
  • Comparison of the inhibitory effects of TNF alpha inhibitors on TNFR1 versus TNFR2.

Main Results:

  • TNFR1 acts as an apoptotic receptor; its inhibition by TNF alpha inhibitors is cardioprotective.
  • TNF alpha inhibitors appear to inhibit TNFR2 more significantly than TNFR1.
  • Greater inhibition of the cardioprotective TNFR2 receptor correlates with cardiovascular morbidity.

Conclusions:

  • The cardiovascular risks associated with TNF alpha inhibitors may stem from excessive inhibition of the cardioprotective TNFR2 receptor.
  • Understanding receptor-specific inhibition is crucial for mitigating cardiovascular side effects in RA treatment.